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ScienceDirectDrug resistance mutations appear in HIV under treatment
pressure. Resistant variants can be transmitted to treatment-
naive individuals, which can lead to rapid virological failure and
can limit treatment options. Consequently, quantifying the
prevalence, emergence and transmission of drug resistance is
critical to effectively treating patients and to shape health
policies. We review recent bioinformatics developments and in
particular describe: (1) the machine learning approaches
intended to predict and explain the level of resistance of HIV
variants from their sequence data; (2) the phylogenetic methods
used to survey the emergence and dynamics of resistant HIV
transmission clusters; (3) the impact of deep sequencing in
studying within-host and between-host genetic diversity of HIV
variants, notably regarding minority resistant variants.
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1Unité Bioinformatique Evolutive, Institut Pasteur, Paris, France
2Sorbonne Université, Collège Doctoral, Paris, France
3Hub de Bioinformatique et Biostatistique, Institut Pasteur, Paris, France
4Centre for the Mathematical Modelling of Infectious Diseases (CMMID),
London School of Hygiene & Tropical Medicine, London, UK
5Department of Infectious Disease Epidemiology, London School of
Hygiene & Tropical Medicine, London, UK
6Usher Institute, University of Edinburgh, Edinburgh, UK
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Introduction
Drug resistance mutations (DRMs) arise in Human
Immunodeficiency Virus-1 (HIV-1) due to antiretroviral
treatment pressure, leading to viral rebound and treat-
ment failure [1,2]. Furthermore, drug-resistant HIV var-
iants can be transmitted to treatment-naive individualsCurrent Opinion in Virology 2021, 51:56–64 and further spread throughout the population over time
[3–5]. These transmitted drug-resistant (TDR) HIV var-
iants limit treatment options and have clinical and public
health implications worldwide. The scale of TDR varies
globally; in the US and Europe, the prevalence of TDR
has decreased or stabilized at between 5% and 15% [6–
11]. However, in resource-limited countries, the preva-
lence of TDR is becoming a pressing health issue [11,12],
with many regions reporting an exponential increase in
prevalence and many surpassing 10% prevalence [13].
Indeed, WHO have suggested that if the prevalence of
TDR exceeds 10% in a country, then first-line regimens
should be reconsidered [14]. Because of this, a number of
countries in Africa and Asia have revised their national
treatment guidelines [12].
There are five main classes of HIV-1 antiretroviral thera-
pies, which target different virus proteins: (i) nucleoside/
nucleotide reverse transcriptase inhibitors (NRTIs), (ii)
non-nucleoside reverse transcriptase inhibitor
(NNRTIs), (iii) protease inhibitors (PIs), (iv) integrase
inhibitors (INIs or INSTIs) and (v) entry inhibitors. The
reverse transcriptase, protease and integrase proteins are
encoded in the pol gene, while the entry inhibitors induce
DRMs in the env gene. NRTIs and NNRTIs date back to
the 80s and are currently the most commonly used drugs.
PIs and INIs appeared more recently, in the mid-90s, and
are still in development [15,16]. PIs and INIs are associ-
ated with lower levels of resistance compared to reverse
transcriptase-based therapy. INIs are increasingly used in
first-line regimens in the presence of NNRTI resistance
at the population level [12]. In total, there are 25
available drugs, all of which are associated with known
DRMs. A list of DRMs is regularly updated [17] by a
consortium of international experts, who select and clas-
sify the DRMs to be surveilled (175 in total) based on
genotype analyses, phenotypic resistance tests and clini-
cal outcome in patients on antiretroviral therapies. Pri-
mary DRMs directly confer resistance to treatments, but
some mutations have an accessory role, increasing drug
resistance when appearing alongside primary DRMs,
while others seem to have a compensatory role and reduce
the fitness cost for primary DRMs. All this, combined
with the development of new antiretroviral drugs [16,18]
and the use of antiretroviral treatments in high-risk
populations by pre-exposure prophylaxis [19,20], makes
it particularly important to further our understanding ofwww.sciencedirect.com
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drug resistance, and survey the emergence of resistant-
HIV transmission clusters in infected populations, espe-
cially in low-income countries.
For all these endeavors to advance, bioinformatics meth-
ods and large well-curated sequence databases are essen-
tial. The Stanford HIV Drug Resistance Database
(https://hivdb.stanford.edu/) is the largest public reposi-
tory and most widely used online resource for HIV drug
resistance. It currently comprises: (1) 450 000 sequences
(reverse transcriptase, protease or integrase) from 200
000 patients with treatment status, from all around the
word; (2) 60 000 results of drug susceptibility assays
from HIV-1 virus isolates; (3) clinical outcome data from
15 clinical trials; (4) many software programs and web
services to query this data. Several countries and regions
have set up national databases of HIV sequences gener-
ated through routine resistance genotyping. These repos-
itories link genotypic data with anonymized clinical and
demographic information, and are regularly updated,
making these national databases an attractive resource
to study and monitor drug resistance. However, due to the
sensitive nature of patient-derived information, the con-
tent of these national databases is non-public and only
available on request. The main national/regional HIV
drug resistance repositories include: (i) The UK HIV
Drug Resistance Database (https://www.hivrdb.org.uk/),
which is the central repository for resistance tests per-
formed as part of routine clinical care throughout the UK
since 2001. It currently comprises over 165 000 test
results, most in the form of annotated pol gene sequences
and includes over 60% of the newly diagnosed patients in
the UK, with linked clinical data available for the majority
of patients. (ii) The Swiss HIV Cohort Study Drug
Resistance Database (http://www.shcs.ch/) that includes
data and meta-data from over 80% of new diagnoses in
Switzerland. (iii) The PANGEA database [21] with data
from sub-Saharan Africa, a radically different region
where the pandemic started and is of great concern, which
holds over 12 000 nearly complete HIV-1 genomes, with
basic-to-extensive associated epidemiological metadata.
In the following, we describe the main approaches to
decipher this data, and the potential of Next Generation
Sequencing (NGS) to better understand and survey the
emergence of DRMs and their transmission.
Machine learning approaches to study and
predict resistance
The presence of DRMs before the start of an antiretrovi-
ral therapy regimen is a strong predictor of the success or
failure of that regimen. Resistance testing using DNA
sequencing is performed routinely in upper-income coun-
tries, and with increasing frequency in low-income and
middle-income countries. To this end, computer pro-
grams are used to analyze the virus sequence of thewww.sciencedirect.com patient (i.e. the virus genotype) and predict the level
of resistance of this sequence to available drugs (i.e. the
resistance phenotype of the virus). Computer programs
can also be used to optimize the combination of multiple
drugs [22].
The standard approach to predict the level of resistance of
HIV sequences (either in the reverse transcriptase, pro-
tease or integrase proteins) is to rely on known resistance
mutations to various antiretroviral therapies. HIVdb [23]
uses expert rules to combine mutations (primary or acces-
sory) observed in the studied sequences, while
WebPSSM [24] uses position-specific scoring matrices.
However, machine learning methods are increasingly
used for this purpose, often via web services [25,26].
These methods first learn a statistical model from a set
of training examples, that is, virus sequences and their
resistance level measured experimentally using Pheno-
Sense assays [27], and then assess the accuracy of the
learned model using an independent set of testing exam-
ples or a cross-validation procedure. We distinguish clas-
sification methods, which predict the effectiveness of a
given antiretroviral therapy [28], and regression
approaches, which predict the fold resistance ratio of
the given sequence compared to the wild type [29]. Initial
approaches were based on decision trees [30], support
vector machines [25], logistic regression [31] and neural
networks [29]. The latter showed higher accuracy (on
average 85%) than the rule-based methods used, for
instance, by HIVdb (70%) [29].
Deep learning models (i.e. neural networks with complex
architectures and a large number of hidden neurons [32])
are a major focus in current machine learning research and
have been successfully applied to many biological pro-
blems [33]. Moreover, recent methods make it possible to
map model outputs back to subsets of the most influential
input features [34]. This approach was explored by Stei-
ner et al. [28], who evaluated the performance of three
deep learning architectures (multilayer perceptron, bidi-
rectional recurrent neural network, and convolutional
neural network) for drug resistance prediction using
genotype-phenotype data available from HIVdb, as train-
ing and testing data (via cross-validation). The resistance
to 18 antiretroviral therapies was learned from 2100
sequences associated with PI susceptibility, 1800
sequences associated with NNRTI susceptibility, and
2100 sequences associated with NRTI susceptibility
(measured by PhenoSense assays [27], as for PI and
NNRTI data). The accuracy of convolutional neural
networks ranged from 86% to 96% and a large number
of known DRMs were among the most influential input
features. Authors suggest that other influential mutations
could also be associated with resistance. These findings
underscore the gain in accuracy brought by machine
learning approaches, compared to rule-based methods
(e.g. HIVdb). However, the main limitation is the lowCurrent Opinion in Virology 2021, 51:56–64
58 Virus bioinformaticsnumber of available sequences with drug susceptibility
measurement given that deep learning is commonly used
with much larger data sets (>10 000 and frequently >100
000 training examples).
Another approach was explored in Ref. [35] to study
resistance patterns, epistasis and discover new DRMs
using: (i) A much larger reverse transcriptase sequence
dataset (55 000 sequences) for training; (ii) A classifica-
tion task to discriminate treatment-naı̈ve from treatment-
experienced sequences; (iii) Simpler machine learning
models, such as random forest and logistic regression; (iv)
Testing on a very different African dataset with subtypes
not seen in the training data to improve robustness and to
limit the impact of phylogenetic confounding factors.
These choices were made with one goal in mind:
interpretability, because it allows the easy extraction of
mutations associated with resistance from important
(influential) classifier features. To summarize, more
DRMs are expected among treated patients than among
naı̈ve ones, even if we expect some DRMs to be present
among naı̈ve patients due to TDRs. To extract DRMs we
can then perform tests (e.g. exact Fisher tests [36]) or use
more advanced, interpretable machine learning methods
[35]. To confirm and further explore the nature of newly
discovered resistance associated mutations, the training
process was repeated after removing features and
sequences corresponding to known DRMs (Figure 1a).
This approach allowed the finding of six new potential
accessory mutations. Two of these are L228H and L228R
(i.e. mutations from L to H and L to R, respectively, at
reference position 228 of reverse transcriptase), which are
spatially very close to both the active and regulatory sites
of reverse transcriptase (Figure 1b), and are overrepre-
sented in sequences containing known DRMs
(Figure 1c.1 and c.2).
Phylogenetic methods to decipher the spread
of resistance
Following acquisition under treatment pressure, DRMs
and resistance-associated mutations can be transmitted to
treatment naı̈ve patients. We distinguish acquired and
transmitted drug resistances (TDRs). TDRs can be fur-
ther separated into those corresponding to treated-to-
naı̈ve versus naı̈ve-to-naı̈ve transmissions. The latter
are particularly problematic, as they can cause the emer-
gence of resistance clusters in the naı̈ve population. On
the other hand, DRMs have some fitness cost and in the
absence of treatment they tend to be reverted to the wild
type amino acid. Some DRMs have been shown to revert
rapidly (e.g. M184V in reverse transcriptase, associated to
NRTIs [37,38]), while others have a low fitness cost (e.g.
L90M in protease [39]) and tend to induce large resis-
tance clusters ([40]; Figure 2).
Traditionally, for routine resistance genotyping a unique
consensus virus sequence per patient is used toCurrent Opinion in Virology 2021, 51:56–64 characterize the variants infecting a given individual,
and phylogenetic trees are inferred from these consensus
sequences to study the emergence, transmission and
reversion of DRMs at the population level. In these trees,
sequences that cluster together represent transmission
clusters and each of the internal tree nodes corresponds to
a transmission event. However, with one sequence per
patient one cannot infer the direction of transmission, that
is, distinguish the transmitter and recipient partners
corresponding to a given tree node. With multiple
sequences per patient, as obtained from NGS, phyloge-
netic methods help to infer the most likely transmission
history [41]. However, reliably identifying the direction of
transmissions remains challenging [42] and depends on,
among other factors, the genetic diversity captured in the
virus sequences of the individuals [43]. To summarize,
the genetic diversity of the virus is expected to be
significantly higher for the transmitter than for the recipi-
ent, but both can be similar, for example, when the
infection dates are close. Moreover, one can never rule
out the possibility of an intermediate, unsampled indi-
vidual. Despite these limitations, phylogenetic inference
has proved a promising tool for the population-level
analysis of HIV resistance transmission. For example,
phylogenetic tools are key in the PANGEA project
[21] to analyze the source-sink dynamics in several
Sub-Sahara African settings, aiming to find generalizable
characteristics of transmitters and transmission events,
and guide recommendations for HIV treatment and pre-
vention policies.
To decipher DRM transmissions, the most likely trans-
mission clusters are extracted from the phylogeny.
Genetic clusters correspond to well-supported subtrees
that contain sequences closely related to each other and
distant from the rest of the tree based on user-defined
genetic thresholds [45]. A genetic cluster can be inter-
preted as representing a recent outbreak, for example,
when a virus acquires a DRM and the patient starts
transmitting the resistant virus. If most of the individuals
in this cluster contain the same DRM, they form a
resistance cluster, from which the number of within-
cluster naı̈ve-to-naı̈ve TDRs can be estimated. This
approach was used to study TDRs in Switzerland
[46,47], Denmark [48], Ethiopia [49] and the USA [50].
The second approach refines the previous one by using
ancestral state reconstruction of a binary character
describing the presence/absence of the studied DRM.
Tree tips are annotated using the presence or absence of
mutations, and the internal node states are inferred using
parsimony [4] or maximum-likelihood [51] methods.
The clusters are defined by subsets of tips and nodes,
all of which have the same resistance status and descend
from a unique node corresponding to the first within-
cluster transmission. Isolated, resistant tips with treat-
ment-experienced status are interpreted as acquired drugwww.sciencedirect.com
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Detecting resistance associated mutations using machine learning.
This figure is adapted from Ref. [35]. The authors used a large UK dataset (n = 55 539) of reverse transcriptase sequences from HIV patients,
who have received treatment or not [44]. Sequences from this dataset were encoded as binary vectors where each feature corresponded to a
specific mutation. These vectors were used to train classifiers, logistic regression (LR) and a Fisher-test-based classifier (FC), to discriminate
between treatment-experienced and treatment-naı̈ve sequences. These classifiers were then evaluated on a smaller and phylogenetically very
different African dataset (n = 3990) using the adjusted mutual information (panel (a)). This criterion measures how well the classifiers discriminate
the two types of sequences (0: random classifier; 10 = 1: perfect classifier) and can be used to compute a p-value to see if the results are truly
different to ones from a random classifier (an asterisk denotes a p-value  0.05). In panel (a), when all features are kept, both classifiers have high
(close to 1), highly significant discriminatory power. In order to check where this power comes from, the authors did the same procedure, but this
time removing features corresponding to known DRMs from the encoded vectors. The adjusted mutual information is lower than when using the
full vectors, but still significantly better than random. Finally, the authors repeated the procedure after removing all sequences that had at least
one known DRM from the training set. This time the adjusted mutual information indicates that the classifiers are no better than random. This
shows that even after removing known DRMs from the data, there remains some resistance-associated information in the sequences, which
differentiates treatment-naı̈ve and treatment-experienced sequences. Furthermore, this information seems to be in the sequences that already
contained DRMs, meaning that it most likely corresponds to accessory mutations that appear alongside known DRMs. By examining the LR and
FC classifiers, we can extract the most important mutations in their decision-making; L228H and L228R of reverse transcriptase are two such
mutations studied in Ref. [35]. Site 228 in panel (b) is positioned right between the active site (where NRTIs act) and the regulatory ‘NNIBP’ site
(where NNRTIs act). To check the accessory nature of these mutations, the authors computed relative risk between L228R/H and known DRMs.
For a given known DRM, the relative risk corresponds to the prevalence of L228R/H in sequence that have that DRM, divided by the prevalence
of L228R/H in sequences that do not have that DRM. In panels (c.1) and (c.2), relative risks for L228R and L228H are shown with their 95%
confidence intervals. These relative risks show that L228R and L228H are highly overrepresented both in sequences that contain DRMs to NRTI
and NNRTI. This, as well as the physical proximity of site 228 to the sites where both classes of drugs operate, point to a potential role as
accessory mutations to known DRMs.
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Emergence and transmission of resistance in protease (mutation L90M, subtype B, UK).
Ancestral state reconstruction of the presence/absence of DRM L90M over time was performed and visualized by PastML [51] on a phylogenetic
tree inferred from 39 224 UK subtype B pol gene sequences [44] with RAxML-NG [52] and dated with LSD2 [60]. Resistance status was detected
with sierrapy [23]. A sensitive resistance status for all tree nodes and tips before 1995 (year of acceptance of Saquinavir, the first antiretroviral
therapy that can provoke L90M DRM) was imposed as in Ref. [61]. Circles denote clusters of samples with the same L90M state (green when the
mutation is absent, orange for resistant strains); the sample sizes of clusters are indicated in the labels, for example, the circle ‘resistant 119’
represents the largest resistance cluster in 2016 (119 patients). Clusters with a ‘0’ and two colors indicate internal tree nodes for which both
resistant and sensitive states had similar marginal probabilities. Arrows between two circles denote transmissions from the top to the bottom
cluster (i.e. acquired drug resistances correspond to the sensitive-to-resistant transmissions, while reversions correspond to the resistant-to-
sensitive ones). The size and the number on top of the arrows indicate that the arrows represent multiple transmission events leading to clusters
of similar sizes (e.g. the arrow of size 483 represents 483 acquired drug resistances). Overall, we see both a large number of independent
acquisitions of drug resistance (arrows from green to orange circles), and the emergence of resistance clusters (orange circles of size >1). As
expected, we do not see any resistance cluster in 1998, and small ones in 2005 (19 patients). We also see a substantial amount of reversions (e.
g. 9 + 15 from the largest 2016 resistance cluster).resistances (83% in average, in UK subtype B [4]), while
in resistance clusters we mostly observe naı̈ve-to-naı̈ve
TDRs (70% in average, in UK subtype B [4]). Rever-
sions correspond to non-resistant tips and clusters des-
cending from a resistance cluster. This approach is illus-
trated in Figure 2, where we used maximum-likelihood
[52] to build a large tree containing 39 224 subtype B
sequences from the UK, and infer [51] the resistance
status of all tree nodes for the L90M protease DRM. This
mutation has a low fitness cost (see above), which likely
explains its high frequency and high probability of trans-
mission between treatment-naı̈ve individuals, resulting in
large resistance clusters and low reversion rate [4].
Next-generation sequencing, resistant
minority variants
Standard population-based Sanger sequencing provides
the genotypes of the predominant variants in a patient,Current Opinion in Virology 2021, 51:56–64 but fails to detect resistant minority variants present in
less than 20% of the total viral population [53]. By
contrast, next generation sequencing (NGS)-based pipe-
lines not only lower sequencing costs, but also enable
reliable and specific detection of resistant variants
accounting for 2% of the viral population [54,55].
NGS is thus becoming the new standard for genotypic
drug resistance testing for HIV [56,57,58,59].
Resistant minority variants are suspected to cause viro-
logical failures that are difficult to predict using Sanger
sequencing when their frequency is below 20%. In fact,
the clinical impact of resistant minority variants is not
uniform across drug classes and depends on the genetic
barrier to resistance to specific drugs. NNRTIs in partic-
ular have a low genetic barrier (a single DNA mutation
can drastically affect drug susceptibility) and many stud-
ies [62] have shown that resistant minority variants maywww.sciencedirect.com
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there is increasing evidence showing that resistant minor-
ity variants increase the risk of treatment switches and
DRM accumulation [63]. All this, combined with the fact
that NGS enables the quantification of DRM frequencies
(and not solely their detection, as with Sanger sequenc-
ing), led to the development of many software pipelines
to extract and quantify resistant minority variants from
NGS data [55]. For example, Hivmmer [64] is an align-
ment and variant-calling pipeline for Illumina HIV deep
sequences, based on the probabilistic aligner Hmmer
[65]. While the main pipelines are able to detect and
quantify DRM frequencies [55], there is still a need for
standardization and quality assurance [57]. Moreover, to
our knowledge, no tool to predict resistance to major
drugs of a representative sample of variants hosted by
a patient exists for NGS data.
Resistant minority variants are also suspected to play a
part in the transmission of DRMs. The study of a large
international cohort of naı̈ve patients using NGS resulted
in the detection of a large fraction of DRMs correspond-
ing to minority variants, which would not have been
detected by traditional Sanger sequencing [59]. Phylo-
genetic analyses [58,66] indicate that some of these rare
variants likely result from transmissions. However, care-
ful analysis of resistance clusters favors the hypothesis
that most resistant minority variants found in naı̈ve
patients are likely generated de novo as a result of repli-
cation errors [66].
Finally, new tools specifically designed for parsing the
large volume of information contained within NGS data-
sets have recently begun to gain traction. For example, by
simultaneously analyzing within-host and between-host
pathogen sequences, phyloscanner [41] provides unprec-
edented resolution into the transmission process, allowing
inference of the direction of transmission, the identifica-
tion of TDRs and the detection of multiply infected
individuals. Such an approach combined with rich
NGS data and metadata should be of great help in
phylodynamic studies [67].
Perspectives
HIV drug resistance surveillance is essential to track
TDR trends and shape first-line regimen recommenda-
tions, especially in low-income countries where DRMs
are frequent, often multiple, and tend to increase
[12,14,36,68]. We are at a crossroads where NGS should
occupy a major place in HIV resistance surveillance and
clinical care, thanks to its decreasing costs and ability to
reveal resistant minority variants and study their impact.
However, adoption of NGS-based HIV resistance geno-
typing poses pressing challenges [56,57], especially for
low-income countries, where they are most needed
[58,69]. In particular, there is a need for standardized
analyses, validated pipelines, and public large-scalewww.sciencedirect.com databases providing not only the within-host diversity
of the virus at different time points, but also rich patient
metadata (e.g. treatment history). In this context,
machine learning and phylogenetic approaches are
expected to play a major role, as they have already done
with Sanger sequencing. Moreover, the use of modeling
should increase to develop and monitor first-line and
second-line treatment regimens [70], and to characterize
the impact of DRMs [71]. Lastly, the analysis of trans-
mission networks [39,72–74] should help us gain further
insight in HIV drug resistance surveillance.
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Aubert V, Klimkait T, Taffé P, Furrer H et al.: Treatment-naive
individuals are the major source of transmitted HIV-1 drug
resistance in men who have sex with men in the Swiss HIVwww.sciencedirect.com cohort study. Clin Infect Dis 2014, 58:285-294 http://dx.doi.org/
10.1093/cid/cit694.
48. Audelin AM, Lohse N, Obel N, Gerstoft J, Jørgensen LB: The
incidence rate of HIV type-1 drug resistance in patients on
antiretroviral therapy: a nationwide population-based Danish
cohort study 1999–2005. Antivir Ther 2009, 14:995-1000 http://
dx.doi.org/10.3851/IMP1412.
49. Arimide DA, Abebe A, Kebede Y, Adugna F, Tilahun T, Kassa D,
Assefa Y, Balcha TT, Björkman P, Medstrand P: HIV-genetic
diversity and drug resistance transmission clusters in Gondar,
Northern Ethiopia, 2003-2013. PLoS One 2018, 13 http://dx.doi.
org/10.1371/journal.pone.0205446.
50. Rhee S-Y, Clutter D, Fessel WJ, Klein D, Slome S, Pinsky BA,
Marcus JL, Hurley L, Silverberg MJ, Kosakovsky Pond SL et al.:
Trends in the molecular epidemiology and genetic
mechanisms of transmitted human immunodeficiency virus
type 1 drug resistance in a large US clinic population. Clin
Infect Dis 2019, 68:213-221 http://dx.doi.org/10.1093/cid/ciy453.
51.

Ishikawa SA, Zhukova A, Iwasaki W, Gascuel O: A fast likelihood
method to reconstruct and visualize ancestral scenarios. Mol
Biol Evol 2019, 36:2069-2085 http://dx.doi.org/10.1093/molbev/
msz131
PastML is a fast maximum likelihood method and tool for ancestral
scenario reconstruction and visualization on phylogenetic trees. It uses
decision-theory concepts to associate each node in the tree to a set of
likely states. Its application to HIV1-C data set inferred many cases of
independent emergence of resistance mutations under treatment pres-
sure, and detected few resistance clusters, corresponding to transmis-
sions among untreated patients.
52. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A: RAxML-
NG: a fast, scalable and user-friendly tool for maximum
likelihood phylogenetic inference. Bioinformatics 2019,
35:4453-4455 http://dx.doi.org/10.1093/bioinformatics/btz305.
53. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL,
Swanstrom R, D’Aquila RT, Gorder MV, Holodniy M, Lloyd Robert
M et al.: Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin
Microbiol 2003, 41:1586-1593 http://dx.doi.org/10.1128/
JCM.41.4.1586-1593.2003.
54. Fogel JM, Bonsall D, Cummings V, Bowden R, Golubchik T, de
Cesare M, Wilson EA, Gamble T, del Rio C, Batey DS et al.:
Performance of a high-throughput next-generation
sequencing method for analysis of HIV drug resistance and




Lee ER, Parkin N, Jennings C, Brumme CJ, Enns E, Casadellà M,
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